Humanized immunomodulatory monoclonal antibodies for the treatment of immunodeficiency
US7981416B2 · kind B2 · utility
25Cited by
8References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 18, 2009 |
| Grant date | Jul 19, 2011 |
| Priority date | — |
| Expiry date | Jan 9, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/73
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from an immune deficiency.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.